Cargando…
Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria
Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.
Autores principales: | Borrmann, Steffen, Peto, Tim, Snow, Robert W, Gutteridge, Win, White, Nicholas J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2586344/ https://www.ncbi.nlm.nih.gov/pubmed/19018658 http://dx.doi.org/10.1371/journal.pmed.0050227 |
Ejemplares similares
-
Rectal artesunate suppositories for the pre-referral treatment of suspected severe malaria
por: Watson, James A., et al.
Publicado: (2023) -
Intermittent Presumptive Treatment for Malaria
por: White, Nicholas J
Publicado: (2005) -
Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria
por: Stepniewska, Kasia, et al.
Publicado: (2006) -
Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal
por: Faye, Babacar, et al.
Publicado: (2007) -
The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies
por: Boni, Maciej F., et al.
Publicado: (2016)